Benzodiazepines and Related Sedatives - 23/11/21

, Kenneth L. Morford, MD b, Ximena A. Levander, MD, MCR a 
Résumé |
Benzodiazepine and related sedative use has been increasing. There has been a growing number of unregulated novel psychoactive substances, including designer benzodiazepines. Benzodiazepines have neurobiological and pharmacologic properties that result in a high potential for misuse and physical dependence. Options for discontinuing long-term benzodiazepine use include an outpatient benzodiazepine taper or inpatient withdrawal management at a hospital or detoxification facility. The quality of evidence on medications for benzodiazepine discontinuation is overall low, whereas cognitive behavioral therapy has shown the most benefit in terms of behavioral treatments. Benzodiazepines may also have significant adverse effects, increasing the risk of overdose and death.
Le texte complet de cet article est disponible en PDF.Keywords : Hypnotics and sedatives, Benzodiazepines, Substance withdrawal syndrome, Drug tapering, Designer drugs, Substance-related disorders
Plan
Vol 106 - N° 1
P. 113-129 - janvier 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
